Trial Profile
A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 26 Mar 2021 Status changed from recruiting to completed.
- 14 Feb 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2023.
- 14 Feb 2020 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2022.